Despite headwinds for its multiple sclerosis (MS) franchise, Biogen (NASDAQ: BIIB) has been on a roll lately. The biotech won U.S. regulatory approval for spinal muscular atrophy (SMA) drug Spinraza in December. It also spun off its hemophilia business into a new company, Bioverativ, in February.
Biogen CEO Michel Vounatsos sat down at the Cowen & Company Annual Health Care Conference earlier this week to talk about his company’s future. Here are five things Vounatsos said in response to questions at the conference that you won’t want to miss.